BPC-157

What it is

BPC-157 stands for Body Protection Compound 157, and its amino-acid sequence is drawn from a protective protein that occurs naturally in human gastric juice. It is a pentadecapeptide, meaning it is fifteen amino acids long, and it does not occur in this exact free-standing form in the body; researchers synthesize it in the lab to study the biological activity of that sequence in isolation.

Much of the interest in BPC-157 comes from its origin in the digestive tract, where researchers first studied it for protecting the stomach lining from ulcers. That original focus has since broadened into a wide preclinical literature on tissue repair more generally, including how injected BPC-157 affects blood vessel formation, collagen production, and the activity of various growth factors in injured tissue [1][3].

How it is studied

The overwhelming majority of BPC-157 research uses rats and other animal models, testing the peptide by injection into the muscle or abdomen, or given by mouth, across models ranging from chemically induced stomach ulcers to surgically created tendon, muscle, and spinal cord injuries. Study durations vary widely, from single-administration experiments to courses lasting up to 90 days in toxicology testing across several species [1][2][3]. No completed randomized controlled trial in humans has been published.

What studies report

• In rats with chemically induced stomach ulcers, BPC-157 given by injection or by mouth was linked to protection of the stomach lining and faster healing of the ulcer through several different biological routes. [1]
• Toxicology testing across mice, rats, rabbits, and dogs at doses up to 1,000 micrograms per kilogram over 90 days did not turn up serious organ toxicity, supporting a preliminary safety profile in these species. [2]
• In rats with surgically created spinal cord injuries, daily BPC-157 over 30 days was linked to better recovery of movement and less tissue damage compared with untreated animals. [3]

What is not known

Because no completed human trial has been published, there is no direct evidence for how BPC-157 behaves in people, at what amount, or whether the tissue-repair effects seen in rats would appear the same way in human tissue. The animal literature, while large, comes overwhelmingly from research groups connected to the peptide's original discovery, and independent replication by unconnected labs, particularly outside rodent models, remains limited.

Reported adverse findings

• The published multi-species toxicology study did not identify serious adverse effects at the doses and duration tested, though this was an animal safety study rather than a human clinical trial. [2]

Regulatory status

No comparable regulator, including the FDA and Health Canada, has approved BPC-157 for use in humans. The World Anti-Doping Agency added it to its list of prohibited substances in 2022, meaning it is banned at all times for athletes subject to that code, with no therapeutic-use exemption available.